In 2023, the Renin-Angiotensin System medicine sales in Canada stood at a certain value, with subsequent forecasts indicating a steady decline from 2024's 18.3 USD per capita to 17.4 USD per capita by 2028. This represents a cumulative annual growth rate (CAGR) reflecting a gradual decrease over these years.

Over the forecasted period, the year-on-year percentage variation suggests a negative trend, highlighting a consistent decrease in sales value per capita.

Future trends to watch for include potential shifts in healthcare policies or market dynamics that could impact demand or pricing, as well as the introduction of new treatments or generic competition influencing the projected sales trajectory.

Download as XLS

More about Antihypertensive Industry 2025-2029